Format

Send to

Choose Destination
PLoS One. 2011;6(6):e20351. doi: 10.1371/journal.pone.0020351. Epub 2011 Jun 7.

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America. adutt@actrec.gov.in

Abstract

BACKGROUND:

Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung adenocarcinoma, none has yet been reported in squamous cell lung carcinoma.

METHODOLOGY/PRINCIPAL FINDINGS:

Using SNP array analysis, we found that a region of chromosome segment 8p11-12 containing three genes-WHSC1L1, LETM2, and FGFR1-is amplified in 3% of lung adenocarcinomas and 21% of squamous cell lung carcinomas. Furthermore, we demonstrated that a non-small cell lung carcinoma cell line harboring focal amplification of FGFR1 is dependent on FGFR1 activity for cell growth, as treatment of this cell line either with FGFR1-specific shRNAs or with FGFR small molecule enzymatic inhibitors leads to cell growth inhibition.

CONCLUSIONS/SIGNIFICANCE:

These studies show that FGFR1 amplification is common in squamous cell lung cancer, and that FGFR1 may represent a promising therapeutic target in non-small cell lung cancer.

PMID:
21666749
PMCID:
PMC3110189
DOI:
10.1371/journal.pone.0020351
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center